Natco

Natco Pharma Limited (short name: NATCO) is an Indian pharmaceutical company incorporated on 19 September 1981 and headquartered at Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana. It is publicly listed on the NSE and BSE (ticker NATCOPHARM). Reported headcount is roughly 4,000–5,000, and consolidated revenue was about ₹4,780 crore (≈US$570M) in FY2025. Sources: company annual report and website (natcopharma.co.in), FT Markets profile, ICRA rating rationale, Tracxn.

Operations. NATCO describes itself as a vertically integrated, R&D-driven manufacturer of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs), focused on complex generics and niche molecules, principally oncology. Its US business centers on high-barrier Paragraph IV/First-to-File ANDAs (about 44 approved ANDAs and roughly 25–30 Para IV filings as of late 2025), including generic Revlimid (lenalidomide), gCopaxone (glatiramer acetate), gTamiflu (oseltamivir), gAfinitor, gFosrenol and liposomal doxorubicin, often sold through marketing partners. It also has a domestic branded oncology business, an API segment (45+ US DMFs), contract manufacturing, and a crop health sciences division. Subsidiaries operate in the US (Natco Pharma USA LLC), Canada, Brazil, Singapore, Indonesia and the Philippines; in November 2025 it acquired a significant stake in South Africa's Adcock Ingram Holdings.

Litigation posture. NATCO is an operating company, not a patent assertion entity. The database shows one tracked case with NATCO as defendant and none as plaintiff. The venue is the District of New Jersey rather than a plaintiff-friendly NPE venue, consistent with Hatch-Waxman ANDA litigation filed where the brand owner is based.

Notable case. The tracked matter is Celgene Corp. v. Breckenridge Pharmaceutical, Inc. et al., No. 2:19-cv-05804 (D.N.J., filed 14 Feb 2019), a Hatch-Waxman suit over Breckenridge's ANDA No. 210111 for generic pomalidomide (POMALYST), in which NATCO was pleaded as a part owner of the ANDA and Breckenridge's development partner. Related earlier Celgene–Breckenridge/Natco pomalidomide suits include No. 2:18-cv-14715 and No. 2:20-cv-02597, in which NATCO was dismissed by stipulation while agreeing to be bound by judgments against Breckenridge. Separately, NATCO's lenalidomide (Revlimid) settlement with Celgene is a focus of the In re Revlimid & Thalomid Purchaser Antitrust Litigation pay-for-delay MDL, where a motion to dismiss was denied in September 2026; the merits are unadjudicated.